Transplant;Failure,Kidney Clinical Trial
— REMO-HYMAPOfficial title:
A Clinical Pilot Study Investigating the Real-time Dynamics of Glucose, Lactate and Creatinine Concentrations in Marginal Donor Kidneys Undergoing Hypothermic Machine Perfusion
A significant number of deceased donor kidneys donated for transplantation are not used and are thrown away due to lack of ways of checking their condition and function before the operation. This significantly reduces the number of potentially life saving transplants. The researchers wish to run a small pilot study to see if it is possible to improve the way transplant kidneys are assessed before transplantation by measuring how well they filter the blood, and how good their metabolism is. The researchers believe this new method will help transplant surgeons make better decisions about which kidneys to use. This pilot study will look at 10 kidneys obtained from older deceased donors. These kidneys are most at risk of being thrown away because of the condition of the donor they came from. At the hospital, these kidneys are usually put onto a machine which pumps cold preservation solution through them for a couple of hours. This time lets the transplant surgeons see how well or poorly the kidney responds to the flowing fluid. In this study the research team will do exactly the same, but also insert a small probe less than a millimetre in diameter into the kidney and the vein (draining blood pipe) and urine output to monitor a number of chemicals made by the kidney. The researchers believe that the changing levels of these chemicals will give the surgeons much more information than they have now. This probe is removed when the kidney is transplanted. Combining these levels with news of how well the patients recover after surgery will allow the research team to design a much larger study to get the right level of information to change the way surgeons choose kidneys and help more transplants happen in the future.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | April 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - All organs to be used in the study must be intended for transplantation and not already rejected/discarded. - All organs must be sourced from deceased donors through NHSBT in the normal course of clinical activity. - Kidneys must come from marginal or 'imperfect' donors according to current clinical criteria. This typically indicates an age of 60 and over, or 50 and over with one or more premorbid conditions, including renal impairment, cerebrovascular disease, and hypertension. Exclusion Criteria: - Organs from living donors are excluded. - Organs from young healthy donors are excluded. - Organs will be excluded if on the assessment of the clinical team they are not suitable for hypothermic machine perfusion. This indicates organs that have arrived with visible defects, or fall well outside the team's standard criteria for clinical acceptability (excessive time in transit, excessive warm ischaemia time, excessive cold ischaemia time, very poor pre-morbid donor condition). |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Hammersmith Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Accunea Ltd. | Imperial College Healthcare NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post-operative recovery of kidney function | Magnitude of change in patient baseline serum creatinine concentration pre- and post-operatively at 30 days (in umol/L) | 30 days post-operatively | |
Secondary | Reintervention rate | Any need to return the patient to theatre or perform additional procedures following the transplant | 30 days post-operatively | |
Secondary | Primary non-function | Number of participants with no change in serum creatinine concentration from baseline despite transplantation | 30 days post-operatively | |
Secondary | Delayed graft function | Number of days with inadequate graft function following surgery (low urine output, static serum creatinine concentration) | 30 days post-operatively | |
Secondary | Acute rejection | Number of patients experiencing immunological rejection of the organ | 30 days post-operatively | |
Secondary | Post-operative complications | Rates of the most common complications including arterial, venous, or parenchymal thrombosis, ureteric leak or stenosis | 30 days post-operatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05811468 -
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
|
||
Active, not recruiting |
NCT04166149 -
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
|
||
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT03737604 -
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
|
Phase 4 | |
Completed |
NCT03765203 -
Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients
|
N/A | |
Completed |
NCT05809440 -
Effectiveness of 20m-MB in KTR Symptom Control
|
N/A | |
Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
Not yet recruiting |
NCT06396702 -
EASE-SOT Pilot Study
|
N/A | |
Recruiting |
NCT03310905 -
Abdominal Wall Transplant
|
N/A | |
Recruiting |
NCT05613010 -
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
|
N/A | |
Recruiting |
NCT06263257 -
The Effect of Mandala Therapy on Anxiety and Comfort in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT04715412 -
Clinical Pharmacy Guided Patient Counselling and Adherence Support on Renal Transplant Recipients
|
N/A | |
Active, not recruiting |
NCT05449496 -
Dietary Intervention to Improve Kidney Transplant Outcomes
|
N/A | |
Not yet recruiting |
NCT06089473 -
Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates
|
N/A | |
Withdrawn |
NCT04473924 -
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
|
Phase 2 | |
Completed |
NCT03760263 -
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
|
Phase 4 | |
Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03436368 -
Continuous Spinal Anesthesia in Renal Transplantation
|
N/A | |
Not yet recruiting |
NCT03322709 -
Minimally Invasive Kidney Transplantation
|
N/A | |
Recruiting |
NCT03778944 -
Enhancing Renal Graft Function During Donor Anesthesia
|
N/A |